Basic Information
Clone | Epratuzumab Biosimilar |
---|
Molecular Weight | 150 kDa |
---|
Endotoxin | <1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay |
---|
Sterility | 0.2 μm filtration |
---|
Aggregation | <5% Determined by SECP |
---|
Purity | >95% Determined by SDS-PAGE |
---|
Product Information
Production | Purified from cell culture supernatant in an animal-free facility |
---|
Purification | Protein A or G purification |
---|
Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
---|
Target Background
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
Immunogen Information
Isotype | Human IgG1 kappa |
---|
Immunogen | Human CD22 |
---|
RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody |
---|
Recommended Dilution Buffer | 1×PBS pH 7.0 |
---|
* For research use only. Not for therapeutic or diagnostic purposes.